Global Rare Hemophilia Factors Market Size & Outlook
Global rare hemophilia factors market, 2018-2030 (US$M)
Related Markets
Global rare hemophilia factors market highlights
- The global rare hemophilia factors market generated a revenue of USD 338.3 million in 2024 and is expected to reach USD 490.4 million by 2030.
- The market is expected to grow at a CAGR (2025 - 2030) of 6.4% by 2030.
- In terms of segment, factor vii deficiency accounted for a revenue of USD 126.4 million in 2024.
- Factor XIII Deficiency is the most lucrative factor deficiency segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
- Country-wise, India is expected to register the highest CAGR from 2025 to 2030.
Global data book summary
| Market revenue in 2024 | USD 338.3 million |
| Market revenue in 2030 | USD 490.4 million |
| Growth rate | 6.4% (CAGR from 2025 to 2030) |
| Largest segment | Factor vii deficiency |
| Fastest growing segment | Factor XIII Deficiency |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Factor VII Deficiency, Factor XI Deficiency (Hemophilia C), Factor XIII Deficiency, Other Rare Factor Deficiencies |
Other key industry trends
- In terms of revenue, the North America accounted for 38.7% of the global rare hemophilia factors market in 2024.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, India is the fastest growing regional market and is projected to reach USD 26.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Rare Hemophilia Factors Market Scope
Rare Hemophilia Factors Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Baxalta | View profile | 10001+ | Illinois City, Illinois, United States, North America | http://www.baxalta.com |
| Bio Products Laboratory | View profile | 501-1000 | Kingdom City, Missouri, United States, North America | http://www.bplgroup.com/ |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| CSL Ltd | View profile | 32000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | https://www.csl.com |
| Biogen Inc | View profile | 7570 | 225 Binney Street, Cambridge, MA, United States, 02142 | https://www.biogen.com |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Bayer AG | View profile | 99723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | https://www.bayer.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
Global rare hemophilia factors market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare hemophilia factors market will help companies and investors design strategic landscapes.
Factor vii deficiency was the largest segment with a revenue share of 37.36% in 2024. Horizon Databook has segmented the Global rare hemophilia factors market based on factor vii deficiency, factor xi deficiency (hemophilia c), factor xiii deficiency, other rare factor deficiencies covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Rare Hemophilia Factors Factor Deficiency Outlook (Revenue, USD Million, 2018-2030)
- Factor VII Deficiency
- Factor XI Deficiency (Hemophilia C)
- Other Rare Factor Deficiencies
- Factor XIII Deficiency
- Global Rare Hemophilia Factors Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Plasma-Derived Therapies
- Prophylactic Treatments
- Other Drug Classes
- Recombinant Therapies
- Global Rare Hemophilia Factors Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Reasons to subscribe to Global rare hemophilia factors market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global rare hemophilia factors market databook
-
Our clientele includes a mix of rare hemophilia factors market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global rare hemophilia factors market , including forecasts for subscribers. This global databook contains high-level insights into Global rare hemophilia factors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global rare hemophilia factors market size, by regions, 2018-2030 (US$M)
Top 10 countries: Rare hemophilia factors market size, 2024 (US$M)
Global rare hemophilia factors market share, by factor deficiency, 2024 & 2030 (%, US$M)
Rare hemophilia factors market: Opportunity assessment by country
Global rare hemophilia factors market, by region, 2024 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
